TP53 p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient

详细信息    查看全文

• 作者：Juliana Giacomazzi (1) (2)
  Simone Selistre (2) (3)
  Juliana Duarte (4)
  Jorge Pinto Ribeiro (5) (6)
  Paulo JC Vieira (5)
  Gabriel de Souza Macedo (1) (6)
  Cristina Rossi (1) (7)
  Mauro Czepielewski (8) (9)
  Cristina Brinkmann Oliveira Netto (10)
  Pierre Hainaut (11)
  Patricia Ashton-Prolla (1) (10) (12) (2) (6)
  
• 刊名：BMC Cancer
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：13
• 期：1
• 全文大小：359KB
• 参考文献：1. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, Eden OB, Varley JM: Relative frequency and morphology of cancers in carriers of germline TP53 mutations. / Oncogene 2001,20(34):4621-628. CrossRef
  2. Nichols NM, Matthews KS: p53 unfolding detected by CD but not by tryptophan fluorescence. / Biochem Biophys Res Commun 2001,288(1):111-15. CrossRef
  3. Wong P, Verselis SJ, Garber JE, Schneider K, DiGianni L, Stockwell DH, Li FP, Syngal S: Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. / Gastroenterology 2006,130(1):73-9. CrossRef
  4. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. / Science 1990,250(4985):1233-238. CrossRef
  5. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH: Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. / Nature 1990,348(6303):747-49. CrossRef
  6. Latronico AC, Pinto EM, Domenice S, Fragoso MC, Martin RM, Zerbini MC, Lucon AM, Mendonca BB: An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. / J Clin Endocrinol Metab 2001,86(10):4970-973. CrossRef
  7. Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, DeLacerda L, Rabin M, Cadwell C, Sampaio G: An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. / Proc Natl Acad Sci U S A 2001,98(16):9330-335. CrossRef
  8. DiGiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, Ribeiro RC, Zambetti G, Kriwacki RW: A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. / Nat Struct Biol 2002,9(1):12-6. CrossRef
  9. Hainaut P: Tumor-specific mutations in p53: the acid test. / Nat Med 2002,8(1):21-3. CrossRef
  10. Achatz MI, Olivier M, Le Calvez F, Martel-Planche G, Lopes A, Rossi BM, Ashton-Prolla P, Giugliani R, Palmero EI, Vargas FR: The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. / Cancer Lett 2007,245(1-):96-02. CrossRef
  11. Assump??o JG, Seidinger AL, Mastellaro MJ, Ribeiro RC, Zambetti GP, Ganti R, Srivastava K, Shurtleff S, Pei D, Zeferino LC: Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. / BMC Cancer 2008, 8:357. CrossRef
  12. Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, Le Calvez-Kelm F, Brugiéres L, Vargas FR, Brentani RR, Ashton-Prolla P: Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. / Hum Mutat 2010,31(2):143-50. CrossRef
  13. Pinto EM, Billerbeck AE, Villares MC, Domenice S, Mendon?a BB, Latronico AC: Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. / Arq Bras Endocrinol Metabol 2004,48(5):647-50. CrossRef
  14. Palmero EI, Schüler-Faccini L, Caleffi M, Achatz MI, Olivier M, Martel-Planche G, Marcel V, Aguiar E, Giacomazzi J, Ewald IP: Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. / Cancer Lett 2008,261(1):21-5. CrossRef
  15. Piovezan GC: / Prevalência do alelo R337H no Estado do Paraná. Universidade Federal do Paraná: Masters degree dissertation; 2006.
  16. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, Hwang PM: p53 regulates mitochondrial respiration. / Science 2006,312(5780):1650-653. CrossRef
  17. Park JY, Wang PY, Matsumoto T, Sung HJ, Ma W, Choi JW, Anderson SA, Leary SC, Balaban RS, Kang JG: p53 improves aerobic exercise capacity and augments skeletal muscle mitochondrial DNA content. / Circ Res 2009,105(7):705-12. 711 p following 712 CrossRef
  18. Wang PY, Zhuang J, Hwang PM: p53: exercise capacity and metabolism. / Curr Opin Oncol 2012,24(1):76-2. CrossRef
  19. National Comprehensive Cancer Network (NCCN) Guidelines guidelines 2012. Available from URL: (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#genetics_screening).
  20. American Thoracic Society and American College of Chest Physicians 2003. Available from URL: www.thoracic.org/statements/resources/pfet/cardioexercise.pdf.
  21. Chiappa GR, Ribeiro JP, Alves CN, Vieira PJ, Dubas J, Queiroga F Jr, Batista LD, Silva AC, Neder JA: Inspiratory resistive loading after all-out exercise improves subsequent performance. / Eur J Appl Physiol 2009,106(2):297-03. CrossRef
  22. Ten Harkel AD, Takken T, Van Osch-Gevers M, Helbing WA: Normal values for cardiopulmonary exercise testing in children. / Eur J Cardiovasc Prev Rehabil 2011,18(1):48-4.
  23. Welsman J, Bywater K, Farr C, Welford D, Armstrong N: Reliability of peak VO(2) and maximal cardiac output assessed using thoracic bioimpedance in children. / Eur J Appl Physiol 2005,94(3):228-30. CrossRef
  24. International Agency for Research on Cancer (IARC) TP53 database 2012. Available from URL: http://p53.iarc.fr/Download/TP53_DirectSequencing_IARC.pdf.
  25. Laffan EE, O'Connor R, Ryan SP, Donoghue VB: Whole-body magnetic resonance imaging: a useful additional sequence in paediatric imaging. / Pediatr Radiol 2004,34(6):472-80. CrossRef
  26. Villani A, Tabori U, Schiffman J, Shlien A, Beyene J, Druker H, Novokmet A, Finlay J, Malkin D: Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. / Lancet Oncol 2011,12(6):559-67. CrossRef
  27. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M: Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. / Radiat Med 2004,22(4):275-82.
  28. Ording Müller LS, Avenarius D, Olsen OE: High signal in bone marrow at diffusion-weighted imaging with body background suppression (DWIBS) in healthy children. / Pediatr Radiol 2011,41(2):221-26. CrossRef
  29. Lalloo F, Varley J, Ellis D, Moran A, O'Dair L, Pharoah P, Evans DG, Group EOBCS: Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. / Lancet 2003,361(9363):1101-102. CrossRef
  30. Latronico AC, Pinto EM, Domenice S, Fragoso MC, Martin RM, Zerbini MC, Lucon AM, Mendonca BB: An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. / J Clin Endocrinol Metab 2001,86(10):4970-973. CrossRef
  31. Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG: CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. / J Clin Oncol 2008,26(4):542-48. CrossRef
  32. Adank MA, Jonker MA, Kluijt I, van Mil SE, Oldenburg RA, Mooi WJ, Hogervorst FB, van den Ouweland AM, Gille JJ, Schmidt MK: CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women. / J Med Genet 2011,48(12):860-63. CrossRef
  33. Krüger S, Kinzel M, Walldorf C, Gottschling S, Bier A, Tinschert S, von Stackelberg A, Henn W, Gorgens H, Boue S: Homozygous PMS2 germline mutations in two families with early-onset haematological malignancy, brain tumours, HNPCC-associated tumours, and signs of neurofibromatosis type 1. / Eur J Hum Genet 2008,16(1):62-2. CrossRef
  34. Toledano H, Goldberg Y, Kedar-Barnes I, Baris H, Porat RM, Shochat C, Bercovich D, Pikarsky E, Lerer I, Yaniv I: Homozygosity of MSH2 c.1906G-C germline mutation is associated with childhood colon cancer, astrocytoma and signs of Neurofibromatosis type I. / Fam Cancer 2009,8(3):187-94. CrossRef
  35. Hagberg JM, Coyle EF, Carroll JE, Miller JM, Martin WH, Brooke MH: Exercise hyperventilation in patients with McArdle's disease. / J Appl Physiol 1982,52(4):991-94.
  36. Ivy JL, Withers RT, Van Handel PJ, Elger DH, Costill DL: Muscle respiratory capacity and fiber type as determinants of the lactate threshold. / J Appl Physiol 1980,48(3):523-27.
  37. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/13/187/prepub
  
• 作者单位：Juliana Giacomazzi (1) (2)
  Simone Selistre (2) (3)
  Juliana Duarte (4)
  Jorge Pinto Ribeiro (5) (6)
  Paulo JC Vieira (5)
  Gabriel de Souza Macedo (1) (6)
  Cristina Rossi (1) (7)
  Mauro Czepielewski (8) (9)
  Cristina Brinkmann Oliveira Netto (10)
  Pierre Hainaut (11)
  Patricia Ashton-Prolla (1) (10) (12) (2) (6)
  
  1. Genomic Medicine Laboratory, Experimental Research Center, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil
  2. Post-Graduate Program in Medicine: Medical Sciences, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil
  3. Pediatric Oncology Service, HCPA, Porto Alegre, Brazil
  4. Radiology Service, HCPA, Porto Alegre, Brazil
  5. Exercise Pathophysiology Research Laboratory and Cardiology Division, HCPA, Porto Alegre, Brazil
  6. Post-Graduate Program in Genetics and Molecular Biology, UFRGS, Porto Alegre, Brazil
  7. School of Medicine, UFRGS, Porto Alegre, Brazil
  8. Department of Internal Medicine, Faculty of Medicine, UFRGS, Porto Alegre, Brazil
  9. Service of Endocrinology, HCPA, Porto Alegre, Brazil
  10. Service of Medical Genetics, HCPA, Porto Alegre, Brazil
  11. International Prevention Research Institute, Lyon, France
  12. Departamento de Genética, UFRGS e Servi?o de Genética Médica e Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, 90035-903, Porto Alegre, RS, Brazil
  
• ISSN：1471-2407

文摘

Background Adrenocortical carcinomas (ACCs) are among the most common childhood cancers occurring in infants affected with the Li-Fraumeni and Li- Fraumeni-like (LFS/LFL) syndromes, which are caused by dominant germline mutations in the TP53 gene. In Brazil, a particular mutation, occurring in the tetramerisation domain of the gene, p.R337H, is exceedingly common due to a founder effect and is strongly associated with ACC. In this report, we describe the phenotype and long-term clinical follow-up of a female child diagnosed with ACC and homozygous for the TP53 p.R337H founder mutation. Case presentation At age 11?months, the patient was diagnosed with a virilising anaplastic adrenal cortical tumour, which was completely excised without disturbing the adrenal capsule. Family history was consistent with an LFL tumour pattern, and genotyping identified the TP53 p.R337H mutation in both alleles in genomic DNA from lymphocytes and fibroblasts. Haplotype analysis confirmed the occurrence of the mutation in the same founder haplotype previously described in other Brazilian patients. No other germline or somatic TP53 mutations or rearrangements were identified. At age 9?years, the child was asymptomatic and had no evidence of endocrine derangements. Full body and brain magnetic resonance imaging (MRI) failed to detect any suspicious proliferative lesions, and cardiopulmonary exercise testing results were within the normal reference for the child’s age, ruling out a major exercise capacity deficiency. Conclusion This is the first clinical and aerobic functional capacity documentation of a patient who carries two mutant TP53 alleles and no wild-type allele. Our results support the hypothesis that TP53 p.R337H, the most common TP53 mutation ever described in any population, is a conditional mutant. Furthermore, our observations over a long period of clinical follow-up suggest that TP53 p.R337H homozygotes do not have a more severe disease phenotype than do heterozygote carriers of the same mutation. Patients with the homozygous TP53 p.R337H genotype will require careful surveillance for lifetime cancer risk and for effects on metabolic capacity later in life.